The share price of Shattuck Labs, Inc. (NASDAQ: STTK) saw a little gain on Thursday during the extended trading session. STTK shares decreased 9.26% to $4.16 at the close of the regular session, but then increased 5.64% to $4.40 in the after-market trading. Even though there were no noteworthy fresh events, the market’s better attitude seemed to be the driving force behind the stock price’s recent surge.
Updated Clinical Trial Data
Shattuck Labs (STTK) last week announced a preliminary result from the Phase 1B dose expansion clinical study of SL-172154 with azacitidine for frontline HR-MDS and TP53-mutant AML patients. On June 14, 2024, Shattuck gave a poster session presentation of his findings at the European Hematology Association (EHA) 2024 Congress. The information emphasized SL-172154’s distinct mode of action and confirmed its status as a top CD47 inhibitor in hematologic malignancies.
Encouraging Results And Future Plans
The latest data reveal an improvement in the complete remission rate since the previous update in December, with additional patients in both cohorts showing continued progress. Due to these promising results, Shattuck Labs is concentrating its efforts on HR-MDS and TP53-mutated AML, areas with significant unmet needs, minimal competition, and potential for expedited approval pathways.
The accumulating evidence highlights the therapeutic potential and manageable safety profile of SL-172154 for patients with previously untreated HR-MDS and TP53-mutated AML. Clinical evidence suggests a pharmacodynamic effect of CD40 activation in the peripheral blood and a developing correlation between clinical remission and CD40-mediated cytokine induction.
Patients treated by Shattuck Labs represent a high-risk group with historically short durations of complete remission and overall survival when treated with azacitidine alone. The median overall survival and duration of remission have not yet been reached.
Shattuck Labs plans to share additional data on treatment durability later this year and is actively enrolling patients in the randomized, controlled expansion cohort for frontline HR-MDS. The company anticipates regulatory discussions later this year to define the registration strategy for SL-172154.
